

## Diagnosis and Management of Aniridia


BY NASREEN RAEES AHMED, MBBS, RADHIKA TANDON, MD, FRCSEdIN, AND M. VANATHI, MD  
EDITED BY SHARON FEKRAT, MD, AND INGRID U. SCOTT, MD, MPH

**A**niridia is a panocular disorder characterized by varying degrees of iris hypoplasia, reduced visual acuity, and nystagmus secondary to foveal hypoplasia. Other ocular findings include cataract, glaucoma, aniridic keratopathy, and optic disc hypoplasia. It may occur as an isolated finding or may be associated with systemic involvement. The prevalence of aniridia has been reported to be 1 in 40,000 to 100,000, with no gender predilection.

### Genetics and Inheritance

Two-thirds of aniridia cases are dominantly inherited with high penetrance, while the remaining one-third are sporadic with *de novo* mutations. In 90 percent of cases, there is loss of function of one copy (haploinsufficiency) of the *PAX6* gene located on chromosome 11p13. The loss of function is attributed to intragenic mutations in two-thirds of cases and chromosomal rearrangements in the remainder. The *PAX6* gene is hypothesized to be the master control gene for morphogenesis of the eye; it is also involved in the development of the brain, olfactory bulb, gut, and pancreas. The gene encodes for a transcriptional regulator with two DNA-binding domains, one of which is a paired domain, while the other is a homeodomain.

Intragenic mutations most commonly include insertion of a premature termination codon, leading to null mutations. C terminal extensions are also known to occur, which cause



**ANIRIDIA AND A VARIANT.** (1) Typical form of aniridia, marked by almost complete lack of iris tissue. (2) Atypical iris coloboma accompanied by keratopathy.

the open reading frame to continue into the 3' untranslated region. Both of these mutations lead to severe forms of aniridia. Missense mutations due to single amino acid substitutions lead to less severe or variant forms of aniridia.

Chromosomal abnormalities such as deletions involving the *PAX6* region, inversions, and translocations involving the transcription unit can also lead to aniridia. Deletion of the contiguous *WT1* gene on chromosome 11p13 leads to the first of the two hits required to inactivate both alleles of *WT1*, leading to WAGR syndrome.

Other genes implicated in aniridia include *FOXC1*, *PITX2*, and *PITX3*.

### Clinical Features and Management

**Visual acuity.** Although visual acuity is generally low, it is unrelated to the extent of iris hypoplasia. Myopia is seen in 64 percent of aniridia patients, and amblyopia in 37 percent.<sup>1</sup>

**Management.** Refractive correction

significantly improves visual acuity in these patients. Amblyopia, if present, requires prompt treatment.

**Iris.** Iris hypoplasia of varying degrees may be present. The iris may be absent, with only a stump visible on gonioscopy; or there may be atypical iris coloboma (location other than inferonasal), iris hole, lack of iris crypts, or stromal hypoplasia that is evident only on retroillumination. Careful slit-lamp examination is necessary to identify the more subtle iris defects.

**Management.** Light sensitivity can be managed with tinted or photochromic glasses, and wide-brimmed hats may be helpful. (Also see the "Lens" section below for iris implants.)

**Cornea.** Aniridia-associated keratopathy (AAK) secondary to limbal stem cell deficiency (LSCD) occurs in 90 percent of patients. Features include increased central corneal thickness, superficial vascularization, subepithelial fibrosis, progressive corneal opaci-

fication, conjunctivalization, and a highly unstable ocular surface predisposing to recurrent epithelial erosions as well as bacterial ulcers and chronic inflammation. (See the table below for a classification of AAK.<sup>2</sup>)

Impression cytology may show goblet cells suggestive of conjunctivalization. The use of monoclonal antibodies to cytokeratins (CK) allows detection of specific cell lineages. CK 3 and 12, which are specific for corneal and limbal epithelial cells, are reduced in LSCD; while CK 19, which is specific for conjunctival epithelial cells, is increased. Confocal scanning reveals loss of basal and wing cell layers of the epithelium and reduction in subbasal nerves.<sup>3</sup>

**Management.** Patients with mild keratopathy can be managed with topical preservative-free lubricants. Moderate keratopathy is treated with autologous serum and amniotic membrane transplant.

In patients with severe phase 3 keratopathy, stabilizing the corneal surface involves replenishing limbal stem cells through transplantation. Since both eyes are affected, autografts cannot be used. Penetrating or lamellar transplants alone may not help, as the primary pathology is LSCD. Keratolimbal allografts or cultured limbal stem cells over amniotic membranes have been used. The Boston Keratoprosthesis has also been used successfully in AAK.

**Lens.** From 50 to 85 percent of patients develop cataracts by early adulthood. Subluxation of the lens due to weak zonules is more common in

aniridic patients than in unaffected individuals. In addition, the anterior capsule appears to be more fragile.

**Management.** Cataract extraction improves vision, but the surgeon should be prepared to manage complications in eyes with weak zonular fibers.

Postoperatively, there may be rapid progression of keratopathy, secondary glaucoma, and macular edema.

Specialized intraocular lenses that incorporate an artificial iris diaphragm can be used to correct aniridia at the time of surgery. The approval status of these devices varies by country; for example, although they have been available in Europe for years, in the United States they can be implanted only with a compassionate use device exemption.

**Intraocular pressure and glaucoma.** Elevated intraocular pressure (IOP) may be seen in 50 to 75 percent of patients. It usually develops in late childhood and early adulthood as progressive anatomic changes occur in the angle. The angle appears to be open in infancy, with minimal to no coverage of the trabecular meshwork with remnant iris tissue. However, over time, the rudimentary iris stump rotates and covers the trabecular meshwork, resulting in raised IOP. The clinician should keep in mind that, due to increased central corneal thickness, IOP readings may be unreliable in patients with aniridia.

Routine gonioscopy should be performed regularly to monitor the encroachment of iris tissue on the trabecular meshwork. Visual fields should

be assessed periodically.

**Management.** Initially, topical antiglaucoma medications may be used, but glaucoma associated with aniridia requires surgery in the majority of cases. Prophylactic goniotomy is quite effective in preventing or delaying the onset of glaucoma in young patients.

Trabeculectomy is generally the first surgery performed in aniridic glaucoma that is not controlled on medical treatment; however, glaucoma drainage devices are a reasonable alternative.<sup>4</sup> Cyclodestructive procedures are reserved for refractory cases.

**Retina and optic nerve.** Poor vision and nystagmus in patients with aniridia are usually caused by foveal hypoplasia, which may be detected clinically as lack of a foveal reflex on direct ophthalmoscopy, reduced pigmentation, and crossing of vessels through the foveal avascular zone. Optical coherence tomography reveals an absence of foveal depression. In addition, 10 percent of aniridic patients have optic nerve hypoplasia.

**Management.** Although these conditions are not currently amenable to treatment, low vision rehabilitation services may be helpful. (See the “Additional Resources” box on page 50.)

**Systemic Associations**

**WAGR syndrome.** Sporadic aniridia is the most consistent finding in WAGR syndrome, which also includes Wilms tumor (pediatric nephroblastoma), genitourinary abnormalities, and mental retardation. In patients with WAGR, Wilms tumor tends to be

**Classification of Aniridia-Associated Keratopathy Into 3 Phases**

PHASE	EROSION/ULCER	VASCULAR PANNUS	SIGNS & SYMPTOMS
1. Slight limbal insufficiency	Maximum 2 recurring erosions or ulcers within 6 months	Not exceeding 1 mm from the limbic arch	Small disorders in absorption of fluorescein; slight epiphora and photophobia
2. Moderate limbal insufficiency	More than 3 recurring erosions or ulcers within 6 months	Involves at least the peripheral half of the cornea ± subepithelial fibrosis	Permanent instability of the lacrimal film; constant red eye, epiphora, and photophobia
3. Severe limbal insufficiency	Permanent signs of corneal erosion	Central cornea involved	Permanent instability of the lacrimal film; constant red eye, epiphora, and photophobia; loss of vision

**SOURCE:** Lee H et al. *Acta Ophthalmol.* 2008;86(7):708-715. (Based on López-García.<sup>2</sup>)

bilateral and presents earlier than in those without the syndrome. Systemic evaluation should be performed in all children with aniridia, irrespective of family history.

**Gillespie syndrome.** In this rare autosomal recessive syndrome, aniridia is associated with ptosis, cerebellar ataxia, and mental retardation.

**Other associations.** Aniridia may also be associated with central auditory processing deficits causing hearing difficulties.

### Genetic Counseling Considerations

**Isolated aniridia.** Two-thirds of patients with isolated aniridia have a positive family history. Because there is considerable phenotypic variability, the clinician must perform a careful slit-lamp examination on other family members before labeling the mutation de novo. If a parent is affected, each child has a 50 percent chance of having aniridia. If the parents of the proband are unaffected, risk to the siblings is low.

**WAGR syndrome.** Patients with WAGR syndrome are generally infertile; thus, reproductive transmission is significantly reduced. Large WAGR deletions usually arise de novo, so siblings are unlikely to be affected. Rarely, parents with balanced translocations may develop deletions and may transmit the deletion to 50 percent of their offspring. ■

1 Valenzuela A, Cline RA. *Can J Ophthalmol.* 2004;39(6):632-638.

2 López-García JS et al. *Arch Soc Esp Ophthalmol.* 2006;81(8):435-444. [Article in Spanish.]

3 Le Q et al. *Eye (Lond).* 2013;27(6):763-766.

4 Allingham RR et al. *Shields Textbook of Glaucoma.* 6th ed. Philadelphia: Wolters Kluwer; 2010.

*Dr. Ahmed is a resident in ophthalmology; Prof. Tandon is Head of Unit, cornea, keratoplasty, and refractive services; Dr. Vanathi is associate professor, cornea, keratoplasty, and refractive services; all are at Dr. R.P. Centre for Ophthalmic Sciences, AIIMS, New Delhi, India. The authors report no related financial interests.*

## SAVE THE DATE!

*There's strength in numbers.* Lobby on Capitol Hill for ophthalmology's top legislative issues including advocating for fair Medicare physician payment, reducing regulatory burdens and vision research. Meet face-to-face with your Members of Congress and show the might of our members at this important event. It's the most effective way to protect the interests of our profession and our patients.



## CONGRESSIONAL ADVOCACY DAY APRIL 15 - 16, 2015 WASHINGTON, DC

*"Be an advocate for our patients and our profession! Participate in Congressional Advocacy Day and play a vital role in communicating with our national legislators about issues of importance to ophthalmology during these critical times. Join hundreds of your colleagues and me in Washington, DC in 2015!"*

Gregory L. Skuta, MD  
Academy President



## REGISTRATION OPENS IN JANUARY 2015.

**Congressional Advocacy Day  
is open to all Academy members and  
registration is free.**

[www.aao.org/myf](http://www.aao.org/myf)

 **AMERICAN ACADEMY<sup>®</sup>  
OF OPHTHALMOLOGY**  
*The Eye M.D. Association*